PMV Pharma Overview
- Founded
-
2013
- Status
-
Public
- Employees
-
62
- Stock Symbol
-
PMVP
- Share Price
-
$5.76
- (As of Friday Closing)
PMV Pharma General Information
Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
- 8 Clarke Drive
- Suite 3
- Cranbury, NJ 08512
- United States
+1 (609) 000-0000
PMV Pharma Timeline
PMV Pharma Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.76 | $5.45 | $3.84 - $17.77 | $249M | 45.8M | 576K | -$1.63 |
PMV Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (8,739) | 150,961 | 751,847 | 2,380,883 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (79,471) | (76,638) | (57,965) | (34,767) |
| Net Income | (74,012) | (73,317) | (57,846) | (34,440) |
| Total Assets | 253,960 | 270,308 | 331,568 | 365,531 |
| Total Debt | 13,478 | 13,976 | 11,193 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
PMV Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PMV Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PMV Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small
Drug Discovery
Cranbury, NJ
62
As of 2022
00000
0000
0000-00-00
00000000
00000
000000
ris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Iselin, NJ
00
As of 0000
00000
000000000
00000
000000
aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Cambridge, MA
0000
As of 0000
00.000
00000000000
00.000
Add Comparison
PMV Pharma Competitors (65)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Outlook Therapeutic | Formerly VC-backed | Iselin, NJ | 00 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly PE-Backed | Cambridge, MA | 0000 | 00.000 | 00000000000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | Lexington, MA | 000 | 00000 | 000000&0 | 00000 |
| 000000 00000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
| 000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
PMV Pharma Patents
PMV Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4171548-A1 | Combination therapy for treatment of cancer | Pending | 24-Jun-2020 | 0000000000 | |
| US-20230049952-A1 | Methods and compounds for restoring mutant p53 function | Pending | 24-Jun-2020 | 0000000000 | |
| AU-2021297716-A1 | Combination therapy for treatment of cancer | Pending | 24-Jun-2020 | 000000000 | |
| US-20210403945-A1 | Compositions and methods utilizing genetically-modified animals and cells | Pending | 24-Jun-2020 | 00000000000 | |
| EP-4172143-A1 | Companion diagnostic tool for mutant p53 reactivating compounds | Pending | 24-Jun-2020 | A61K31/404 |
PMV Pharma Executive Team (9)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Mack Ph.D | Chief Executive Officer & Board Member | ||
| Winston Kung | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| Deepika Jalota | Executive | ||
| Thomas Shenk Ph.D | Co-Founder & Member of the Scientific Advisory Board | ||
| Richard Heyman Ph.D | Chairman & Member of Scientific Advisory Board |
PMV Pharma Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arnold Levine Ph.D | PMV Pharma | Board Member | 000 0000 |
| Charles Baum Ph.D | Self | Board Member | 000 0000 |
| David Mack Ph.D | PMV Pharma | Chief Executive Officer & Board Member | 000 0000 |
| Douglas Fisher MD | InterWest Health Partners | Board Observer | 000 0000 |
| Kirsten Flowers | PMV Pharma | Board Member | 000 0000 |
PMV Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PMV Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PMV Pharma ESG
Risk Overview
Risk Rating
Updated May, 03, 2023
31.58 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 866
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 420
Rank
00.00
Percentile
